WallStreetZenWallStreetZen

NASDAQ: CARA
Cara Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Be the first to know when Wall Street analysts revise their CARA stock forecasts and price targets.

Forecast return on equity

Is CARA forecast to generate an efficient return?

Forecast return on assets

Is CARA forecast to generate an efficient return on assets?

Company
-145.27%
Industry
32.68%
CARA is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

CARA earnings per share forecast

What is CARA's earnings per share in the next 2 years based on estimates from 1 analyst?

Avg 1 year Forecast
-$4.08
Avg 2 year Forecast
-$3.84

CARA revenue forecast

What is CARA's revenue in the next 3 years based on estimates from 1 analyst?

Avg 1 year Forecast
$3.1M-56.28%
Avg 2 year Forecast
$3.8M-47.46%
Avg 3 year Forecast
$25.2M+253.09%
CARA's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

CARA revenue growth forecast

How is CARA forecast to perform vs Biotechnology companies and vs the US market?

Company
44.94%
Industry
60.47%
Market
10.88%
CARA's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
CARA's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

CARA vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
CARA$5.23N/AN/A
CRIS$2.78$20.00+619.42%Buy
ENLV$1.12$9.50+748.21%Strong Buy
RNXT$0.97$9.00+824.02%Buy
ALLK$0.26$3.00+1,062.79%Buy
View Top Biotech Stocks

Cara Therapeutics Stock Forecast FAQ

What is CARA's earnings growth forecast for 2025-2026?

(NASDAQ: CARA) Cara Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 14.01%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 18.95%.

Cara Therapeutics's earnings in 2025 is -$70,867,000.On average, 1 Wall Street analyst forecast CARA's earnings for 2025 to be -$18,661,227, with the lowest CARA earnings forecast at -$18,661,227, and the highest CARA earnings forecast at -$18,661,227.

In 2026, CARA is forecast to generate -$17,563,562 in earnings, with the lowest earnings forecast at -$17,563,562 and the highest earnings forecast at -$17,563,562.

If you're new to stock investing, here's how to buy Cara Therapeutics stock.

What is CARA's revenue growth forecast for 2025-2027?

(NASDAQ: CARA) Cara Therapeutics's forecast annual revenue growth rate of 44.94% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 60.47%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.88%.

Cara Therapeutics's revenue in 2025 is $7,137,000.On average, 1 Wall Street analysts forecast CARA's revenue for 2025 to be $14,269,651, with the lowest CARA revenue forecast at $14,269,651, and the highest CARA revenue forecast at $14,269,651. On average, 1 Wall Street analysts forecast CARA's revenue for 2026 to be $17,151,023, with the lowest CARA revenue forecast at $17,151,023, and the highest CARA revenue forecast at $17,151,023.

In 2027, CARA is forecast to generate $115,254,871 in revenue, with the lowest revenue forecast at $115,254,871 and the highest revenue forecast at $115,254,871.

What is CARA's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: CARA) forecast ROA is -145.27%, which is lower than the forecast US Biotechnology industry average of 32.68%.

What is CARA's Earnings Per Share (EPS) forecast for 2025-2026?

(NASDAQ: CARA) Cara Therapeutics's current Earnings Per Share (EPS) is -$15.53. On average, analysts forecast that CARA's EPS will be -$4.08 for 2025, with the lowest EPS forecast at -$4.08, and the highest EPS forecast at -$4.08. In 2026, CARA's EPS is forecast to hit -$3.84 (min: -$3.84, max: -$3.84).

What is CARA's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: CARA) forecast ROE is N/A, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.